

Isolation of α -glucosidase inhibitors from hyssop (*Hyssopus officinalis*)

Hideyuki Matsuura^{a,*}, Hiroyuki Miyazaki^a, Chikako Asakawa^a, Midori Amano^a,
Teruhiko Yoshihara^b, Junya Mizutani^c

^aNorthern Advancement Center for Science and Technology, Kita-21, Nishi-12, Sapporo, Hokkaido 001-0021, Japan

^bDivision of Applied Bioscience, Graduate School of Agriculture, Hokkaido University, Sapporo, Hokkaido 060-8589, Japan

^cPlant Ecochemicals Research Center, R&BP Center Bldg. 3F, E-310, 3-1-1, Megumino-kita, Eniwa, Hokkaido 061-1374, Japan

Received 23 June 2003; received in revised form 26 September 2003

Abstract

α -Glucosidase inhibitory activity was found in aqueous methanol extracts of dried hyssop (*Hyssopus officinalis*) leaves. Active principles against α -glucosidase, prepared from rat small intestine acetone powders, were isolated and characterized. The structures of these isolated compounds were determined to be (7*S*, 8*S*)-syringoylglycerol-9-*O*-(6'-*O*-cinnamoyl)- β -D-glucopyranoside and (7*S*, 8*S*)-syringoylglycerol 9-*O*- β -D-glucopyranoside by analysis of physical and spectroscopic data (FDMS, ¹H NMR, ¹³C NMR, HMQC, and HMBC experiments) together with chemical syntheses.

© 2003 Elsevier Ltd. All rights reserved.

Keywords: *Hyssopus officinalis*; Labiatae; Hyssop; α -Glucosidase inhibitor; Diabetes; Syringoylglycerol

1. Introduction

Diabetes is a lifestyle-related disease known to trigger many complications. Recently, the rapid increase in the already large number of patients has become a major health issue. The α -glucosidase complex in the small intestine is involved in sugar absorption. Thus, inhibitors of α -glucosidase would limit the absorption of dietary carbohydrates and in turn suppress postprandial hyperglycemia. Therefore, α -glucosidase inhibitors are promising drug candidates in the treatment and prevention of diabetes. Nojirimycin (Inouye et al., 1968; Reese and Parrish, 1968) and acarbose (Truscheit et al., 1981) are known to be powerful α -glucosidase inhibitors derived from microorganisms. However, the potency of these inhibitors precludes their use in humans without careful medical consultation. In the search for alternative α -glucosidase inhibitors, we speculated that

analysis of the secondary metabolites synthesized by plants would be a promising line of inquiry, since plants are known to have many nutritional and health benefits. We surveyed a number of herbs and edible wild plants for α -glucosidase inhibitors, and reported the inhibitor from balsam pear (*Momordica charantia*) and *Grifola frondosa* (Matsuura et al., 2002). We report here the isolation and characterization of α -glucosidase inhibitors from hyssop.

2. Results and discussion

Extracts were obtained in MeOH–H₂O (7:3) of 13 varieties of herb; yarrow (*Achillea millefolium*), basil (*Ocimum basilicum*), spearmint (*Mentha spicata*), sage (*Salvia officinalis*), rocket (*Eruca vesicaria*), parsley (*Petroselinum crispum*), watercress (*Nasturtium officinale*), lemon balm (*Melissa officinalis*), chervil (*Anthriscus cerefolium*), oregano (*Origanum vulgare*), hyssop (*Hyssopus officinalis*), chamomile (*Matricaria chamomilla*), and tansy (*Tanacetum vulgare*). Each extract was divided into EtOAc and H₂O soluble fractions. The H₂O and EtOAc soluble layers were examined for their inhibitory activities. Both layers of oregano, tansy, and

* Corresponding author at present address: Division of Applied Bioscience, Graduate School of Agriculture, Hokkaido University, Sapporo, Hokkaido 060-8589, Japan. Tel.: +81-11-706-2495; fax: +81-11-706-2505.

E-mail address: matsuura@chem.agr.hokudai.ac.jp (H. Matsuura).

hyssop extract showed inhibitory activities (data not shown). Air-dried leaves of hyssop (1 kg) were soaked in MeOH–H₂O (7:3). The extract was partitioned with EtOAc and H₂O. The H₂O and EtOAc soluble layers were purified by a series of various chromatography techniques to obtain (7*S*, 8*S*)-syringoylglycerol 9-*O*-β-D-glucopyranoside (**1**, 565 mg) and (7*S*, 8*S*)-syringoylglycerol 9-*O*-(6'-*O*-cinnamoyl)-β-D-glucopyranoside (**2**, 90 mg), respectively (Fig. 1). Compound **1** was obtained as a colorless residue with ions at m/z 405 [M–H][–] (negative, matrix:TEA) and 429 [M+Na]⁺ (positive, matrix:glycerol) by FAB-MS spectrometry. The molecular formula of heptaacetyl derivative (**3**), which was derived from **1**, was determined to be C₃₁H₄₀O₁₈ by HR-FD-MS spectrometry. Thus, the molecular formula of **1** was determined to be C₁₇H₂₆O₁₁. Spectroscopic data including the specific




Fig. 1. α-Glucosidase inhibitors isolated from hyssop (*H. officinalis*).

rotation, $[\alpha]_D^{23} -17.7^\circ$ ($c=0.5$, MeOH), agreed well with previously reported data (Kijima et al., 1997), and therefore, the planar structure of **1** was determined to be as in Fig. 1. The analysis of ¹H NMR, ¹³C NMR, DEPT, HMQC, and HMBC spectral data gave the total ¹H and ¹³C assignments for **1**, as in Tables 1 and 2, respectively.

In order to ascertain the absolute configurations of C-7 and 8, compound **1** was converted according to Scheme 1 to afford (7*S*, 8*S*)-4-*O*-methylsyringoylglycerol (**5**), with a specific rotation of $[\alpha]_D^{23} -21.1^\circ$ ($c=0.59$, MeOH). Independently, (7*R*, 8*R*)-4-*O*-methylsyringoylglycerol (**8**) was synthesized according to Scheme 2 using 3, 4, 5-trimethoxycinnamic acid (**6**) as a starting material. Its chirality of (7*R*, 8*R*) was introduced by a reaction of the catalytic asymmetric dihydroxylation developed by Kolb et al. (1994) using the reagent of AD-mix-β, and the total assignment of ¹H for **8** was performed by a ¹H–¹H COSY experiment. The ¹H NMR, IR, and EI-MS spectra of (7*R*, 8*R*)-4-*O*-methylsyringoylglycerol (**8**) agreed well with those of **5**, but the direction of its specific rotation, $[\alpha]_D^{23} -17.0^\circ$ ($c=0.50$, MeOH), was opposite. Therefore, the absolute configurations of C-7 and -8 of **1** were determined to be (7*S*) and (8*S*), respectively. Although the expected $[\alpha]_D^{23}$ of **8** should be close to -21.1° , the observed value was due to incomplete enantio-selectivity of catalytic asymmetric dihydroxylation conducted by our group.

Table 1

¹H NMR (270 MHz, CD₃OD) assignments of **1** and **2**

	1	2
H-2	6.62 (1H, <i>s</i>)	6.62 (1H, <i>s</i>)
H-6	6.62 (1H, <i>s</i>)	6.62 (1H, <i>s</i>)
H-7	4.54 (1H, <i>d</i> , $J=6.2$ Hz)	4.59 (1H, <i>d</i> , $J=6.5$ Hz)
H-8	3.73 (1H, <i>m</i>)	3.73–3.20 (3H, <i>m</i>)
H-9a	3.63 (1H, <i>m</i>)	
H-9b	3.47 (1H, <i>dd</i> , $J=10.0, 3.5$ Hz)	
H-1'	4.15 (1H, <i>d</i> , $J=7.6$ Hz)	4.20 (1H, <i>d</i> , $J=7.6$ Hz)
H-2'	3.30–3.10 (4H, <i>m</i>)	3.73–3.20 (4H, <i>m</i>)
H-3'		
H-4'		
H-5'		
H-6'a	3.73 (1H, <i>m</i>)	4.46 (1H, <i>dd</i> , $J=13.0, 2.1$ Hz)
H-6'b	3.55 (1H, <i>dd</i> , $J=11.6, 5.4$ Hz)	4.23 (1H, <i>dd</i> , $J=13.0, 6.2$ Hz)
H3''		6.43 (1H, <i>d</i> , $J=16.1$ Hz)
H5''		7.58 (1H, <i>d</i> , $J=16.1$ Hz)
H6''		7.49 (1H, <i>m</i>)
H-7''		7.33 (1H, <i>m</i>)
H-8''		7.33 (1H, <i>m</i>)
H-9''		7.49 (1H, <i>m</i>)
Ph–OCH ₃	3.77 (6H, <i>s</i>)	3.73 (6H, <i>s</i>)

Table 2

¹³C NMR (67.5 MHz, CD₃OD) assignments of **1** and **2**

	1	2
C-1	133.6	133.5
C-2	105.3	105.1
C-3	148.9	148.8
C-4	135.9	135.7
C-5	148.9	148.8
C-6	105.3	105.1
C-7	75.5	75.3
C-8	76.0	75.9
C-9	72.0	72.1
C-1'	104.6	104.9
C-2'	71.7 75.2 77.9 78.0	71.8 75.1 75.2 77.7
C-3'		
C-4'		
C-5'		
C-6'	62.8	64.9
C-1''		168.2
C-2''		118.4
C-3''		146.4
C-4''		135.5
C-5''		129.2
C-6''		129.9
C-7''		131.4
C-8''		129.9
C-9''		129.2
Ph–OCH ₃	56.9	56.7

Compound **2** was obtained as a colorless residue and gave a molecular ion at m/z 536 $[M]^+$ by FD–MS spectrometry. Compound **2** was treated with a solution of pyridine and acetic anhydride to afford **9**, whose molecular formula was determined to be $C_{38}H_{44}O_{18}$ (m/z 788.2508 $[M]^+$) by HR–FD–MS spectrometry. Thus, the molecular formula of **2** was determined to be $C_{26}H_{32}O_{12}$. Compounds **1** and **2** showed similar features in their 1H and ^{13}C NMR spectra (Tables 1 and 2), and the acetyl-derivatives also exhibited similar tendencies in 1H and ^{13}C NMR spectra. The ^{13}C NMR resonance of δ 168.2 of **2** suggested that an ester moiety existed in the structure. As shown in Scheme 3, alkaline hydrolysis of **2** afforded **1** and **10**. Compound **10** was identified as cinnamic acid since spectral data of EI–MS, 1H and ^{13}C NMR of **10** agreed closely with those of an authentic specimen of cinnamic acid (data not shown). This result revealed that compound **2** was composed of **1** and cinnamic acid in its ester form, and the partial structures were connected by HMBC correlation to construct the structure of **2** (Fig. 2). The analysis of 1H NMR, ^{13}C NMR, DEPT, HMQC, and HMBC spectral data gave the total 1H and ^{13}C assignments for **2**, as in Tables 1 and 2, respectively.

The inhibitory activities of **1** and **2** were compared with 1-deoxynojirimycin (**11**) (Yoshikuni, 1988) (Fig. 3). Compounds **1** and **2** exhibited 53 and 54% inhibitory activity at the concentration of 3×10^{-3} M, but 1-deoxynojirimycin (**11**) exhibited 58% inhibitory activity at 3×10^{-7} M. Compared with the activity of 1-deoxynojirimycin (**11**), those of **1** and **2** were very low. However, the activity of 1-deoxynojirimycin (**11**) is too potent to administer without medical supervision. On the other hand, hyssop has been consumed as a food material for a long time, thus it has a proven safety record. If the plant is regularly incorporated into the diet, it could compensate for the low α -glucosidase inhibitory activity.







Fig. 2. The important HMBC correlations of compound **2**.



Scheme 1. (a) β -Glucosidase/0.1 N $AcONH_4$ -AcOH buffer (pH 5.6), 37 °C (67%) (b) $CH_2N_2/MeOH$, 0 °C (35%).



Scheme 2. (a) $CH_2N_2/MeOH$ at 0 °C, (b) LAH/THF at 0 °C (28%), (c) AD-mix- β at 4 °C (9%).



Scheme 3. (a) 1% NaOH/EtOH, room temp. (76% for **1**, 74% for **10**).

In our search for α -glucosidase inhibitors from edible plants, compound **1** was rediscovered from hyssop (*H. officinalis*) and we determined its absolute configuration. In addition, a new related compound **2** was identified. It is hoped that these preliminary experiments will provide the basis for further examination of the suitability of hyssop as a medicinal supplement that contributes toward the treatment and prevention of diabetes.

3. Experimental

3.1. General

Fast atom bombardment mass spectra (FAB-MS) were obtained on a Jeol HX-100, and field desorption

mass spectra (FD-MS) and electron impact mass spectra (EI-MS) were on Jeol JMS-O1SG-2 and JMS-DX-300 mass spectrometers, respectively. NMR spectra were recorded on a Bruker AM-500 (^1H at 500 MHz) and Jeol JNM-EX 270 FT NMR system (^1H at 270 MHz; ^{13}C at 67.5 MHz). In the ^1H NMR spectra, chemical shifts are reported using TMS as an internal standard. In the ^{13}C NMR spectra, chemical shifts are reported as δ (ppm) values relative to the carbon signals (δ 49.0) and (δ 77.0) of CD_3OD and CDCl_3 , respectively. IR spectra were on Perkin Elmer System 2000 FT-IR spectrometer.

Medium pressure liquid chromatography (MPLC): EFC-1000 pump (Tokyo Rikakiki, stroke length, 50; stroke rate, 70), Lobar LiChroprep RP-18 (Merck, 440×37 mm), UV-absorbance ($A_{254\text{nm}}$); flash column chromatography (FCC): EFC-1000 pump (Tokyo Rikakiki), Wakogel (Wako Pure chem., C-200); Sephadex LH-20 (Amersham Pharmacia Biotech); Diaion HP-20 (Mitsubishi Chem.); TLC, Merck silica gel 60 F₂₅₄ (Art 5554); HPLC: Hitachi liquid chromatograph L-7000 series system.

3.2. Plant material

Yarrow (*A. millefolium*) grew wild, and basil (*O. basilicum*), spearmint (*M. spicata*), sage (*S. officinalis*), rocket (*E. vesicaria*), parsley (*P. crispum*), watercress (*N. officinale*), lemon balm (*M. officinalis*), and chervil (*A. cerefolium*) were harvested from the experimental field of the Plant Ecochemicals Research Center. Air-dried aerial parts of oregano (*O. vulgare*), hyssop (*H. officinalis*), chamomile (*M. chamomilla*), tansy (*T. vulgare*) were purchased from Koyu-Seikatsu, Inc. (Kitami, Hokkaido, Japan).

3.3. Chemicals

1-Deoxynojirimycin (**11**) and glucose B test were purchased from Wako pure chemical industries, Ltd. Rat intestinal acetone powder, 3, 4, 5-trimethoxycinnamic acid, and AD-mix- β were purchased from Sigma Aldrich Japan Co., Tokyo.

3.4. Assay for rat intestinal α -glucosidase inhibitory activity

The α -glucosidase inhibitory activity was measured according to the described method (Toda et al., 2001). A crude enzyme solution was prepared from rat intestinal acetone powder. Before the amount of glucose derived from sucrose in the reaction mixture was measured, the reaction mixture was passed through an alumina column (1.6 g, ICN Alumina B, ICN Biomedicals GmbH) in order not to hinder the glucose B test by phenolic compounds.




Fig. 3. α -Glucosidase inhibitory activities of **1** and **2** (a) 1-deoxynojirimycin showed its inhibitory activities of 21 and 58% at 1×10^{-8} M and 3×10^{-7} M, respectively; (b) bars represent the means \pm S.D. of three measurements.

3.5. Extraction and separation

Air-dried leaves of hyssop (1 kg, *H. officinalis*) were soaked in MeOH–H₂O (7:3). After filtration using filter paper (No. 1, Toyo), the filtrate was concentrated in vacuo to about 1.5 l. The resulting extract was partitioned between EtOAc (1 l × 3) and H₂O to afford H₂O soluble and EtOAc soluble layers.

3.5.1. Purification (7*S*, 8*S*)-syringoylglycerol 9-*O*-(6'-*O*-cinnamoyl)-β-*D*-glucopyranoside (**1**)

The H₂O soluble layer was concentrated under reduced pressure to about 500 ml. To the concentrated extract was added a solution of EtOH (2 l), and the mixture was allowed to stand at –25 °C for 48 h. The supernatant and precipitation were separated with filter paper (No. 1, Toyo). The solution of the supernatant was concentrated in vacuo, and the resultant oil was subjected to Diaion HP-20 (500 g). The resins were successively washed by H₂O (2.5 l), MeOH–H₂O (7:3) (4 l), and MeOH (2 l). The eluent of MeOH–H₂O (7:3), that exhibited α-glucosidase inhibitory activity, was applied to Sephadex LH-20 (MeOH–H₂O 7:3) to yield an active fraction A, which was subjected to MPLC (MeOH–H₂O–HOAc 50:50:0.1) to give an active fraction B. Further purification of fraction B by HPLC (GL Sciences Inc., Inertsil ODS, 20 × 250 mm, MeOH–H₂O–HOAc 15:85:0.1, flow rate: 2 ml/min, *A*_{254nm}) followed by another purification by HPLC (Kanto chemical Co. Inc., Mightysil RP-18, 4.6 × 250 mm, CH₃CN–H₂O–HOAc 8:92:0.1, flow rate: 1 ml/min, *A*_{254nm}) afforded (7*S*, 8*S*)-syringoylglycerol 9-*O*-(6'-*O*-cinnamoyl)-β-*D*-glucopyranoside (**1**) (565 mg).

3.5.2. (7*S*, 8*S*)-Syringoylglycerol 9-*O*-(6'-*O*-cinnamoyl)-β-*D*-glucopyranoside (**1**)

Colorless oil; $[\alpha]_D^{23}$ –17.7° (*c* = 0.5, MeOH); FAB-MS (positive, matrix: glycerol) *m/z* (rel. int.): 429 [*M* + Na]⁺ (100); FAB-MS (negative, matrix: TEA) *m/z* (rel. int.): 405 [*M* – H][–] (10.8); ¹H NMR (270 MHz, CD₃OD): Table 1; ¹³C NMR (67.5 MHz, CD₃OD): Table 2.

3.5.3. Purification of (7*S*, 8*S*)-syringoylglycerol 9-*O*-(6'-*O*-cinnamoyl)-β-*D*-glucopyranoside (**2**)

The EtOAc-soluble layer was concentrated under reduced pressure, and the resultant black oil was subjected to Diaion HP-20 (500 g). The resins were successively washed by MeOH–H₂O (1:1) (3 l), MeOH–H₂O (7:3) (3 l), and MeOH (3 l). The eluate of MeOH–H₂O (1:1), that showed the inhibitory activities, was applied to a silica gel (Wakogel C-200, Wako Pure Chem., 350 g) CC. The column was successively eluted with CHCl₃ (2 l), MeOH–CHCl₃ (5:95) (1 l), MeOH–CHCl₃ (1:9) (1 l), MeOH–CHCl₃ (3:7) (2 l), and MeOH–CHCl₃ (4:6) (1 l). The eluate of MeOH–CHCl₃ (1:9) and MeOH–CHCl₃ (3:7), that exhibited the inhibitory activities,

were combined and concentrated in vacuo. The resultant black oil was subjected to Sephadex LH-20 (250 g) with solvent MeOH–CHCl₃ (7:3) to afford active fraction C, which was applied to FCC using MeOH–CHCl₃ (1:9) to afford active fraction D. Further purification of fraction D by MPLC (MeOH–H₂O–HOAc 50:50:0.1) followed by another purification by HPLC (YMC, YMC-Pack ODS-AM, 300 × 10 mm, MeOH–H₂O–AcOH 40:60:0.1, flow rate: 2.0 ml/min, *A*_{254nm}) to afford (7*S*, 8*S*)-syringoylglycerol 9-*O*-(6'-*O*-cinnamoyl)-β-*D*-glucopyranoside (**2**) (90 mg).

3.5.4. (7*S*, 8*S*)-Syringoylglycerol 9-*O*-(6'-*O*-cinnamoyl)-β-*D*-glucopyranoside (**2**)

Colorless oil; $[\alpha]_D^{23}$ –31.5° (*c* = 1.0, MeOH); FD-MS *m/z* (rel. int.): 536 [*M*]⁺ (100); ¹H NMR (270 MHz, CD₃OD): Table 1; ¹³C NMR (67.5 MHz, CD₃OD): Table 2.

3.6. Preparation of heptaacetyl derivative (**3**)

To a stirred mixture of **1** in pyridine was added a solution of acetic anhydride, and the reaction mixture was further stirred for 24 h at room temperature. The usual work-up was employed followed by the purification of the extract to afford **3** quantitatively.

3.6.1. Heptaacetyl derivative (**3**)

FD-MS *m/z* (rel. int.) 700 [*M*]⁺ (100); HR-FD-MS *m/z*: 700.2190 [*M*]⁺ (calc. For C₃₁H₄₀O₁₈: 700.2214); IR *v*_{max} (NaCl) cm^{–1}: 2944, 1755, 1222, 1040; ¹H NMR (270 MHz, CD₃OD): δ 6.62 (2H, *s*), 5.92 (1H, *d*, *J* = 8.1 Hz), 5.25 (1H, *m*), 5.22 (1H, *t*, *J* = 9.2, H-3'), 5.06 (1H, *t*, *J* = 9.7 Hz, H-4'), 5.01 (1H, *dd*, *J* = 9.7, 7.8 Hz, H-2'), 4.52 (1H, *d*, *J* = 7.7 Hz, H-1'), 4.24 (1H, *dd*, *J* = 12.2, 4.7, H-6'a), 4.06 (1H, *dd*, *J* = 12.2, 2.4, H-6'b), 3.83 (3H, *s*), 3.66 (3H, *m*), 2.32 (3H, *s*), 2.15 (3H, *s*), 2.09 (3H, *s*), 2.07 (3H, *s*), 2.06 (3H, *s*), 2.02 (3H, *s*).

3.7. Preparation of hexaacetyl derivative (**9**)

To a stirred mixture of **2** in pyridine was added a solution of acetic anhydride, and the reaction mixture was further stirred for 24 h at room temperature. The usual work-up was employed followed by the purification of the extract to afford **9** quantitatively.

3.7.1. Hexaacetyl derivative (**9**)

FD-MS *m/z* (rel. int.): 788 [*M*]⁺ (100), 494 (40); HR-FD-MS *m/z*: 788.2508 [*M*]⁺ (calc. For C₃₈H₄₄O₁₈: 788.2527); IR *v*_{max} (NaCl) cm^{–1}: 2944, 1756, 1219, 1038; ¹H NMR (270 MHz, CDCl₃): δ 7.65 (1H, *d*, *J* = 16.0 Hz), 7.50 (2H, *m*), 7.35 (3H, complex), 6.59 (2H, *s*), 6.40 (1H, *d*, *J* = 16.0 Hz), 5.90 (1H, *d*, *J* = 7.9 Hz), 5.24 (1H, *m*), 5.22 (1H, *br.t.*, *J* = 9.4 Hz), 5.07 (1H, *br.t.*, *J* = 10.0 Hz), 4.92 (1H, *dd*, *J* = 9.5, 7.8 Hz), 4.52 (1H, *d*, *J* = 7.6

Hz), 4.26 (2H, *m*), 3.78 (6H, *s*), 3.74–3.56 (3H, complex), 2.26 (3H, *s*), 2.12 (3H, *s*), 2.04 (3H, *s*), 2.02 (3H, *s*), 2.00 (3H, *s*), 1.99 (3H, *s*). ^{13}C NMR (67.5 MHz, CDCl_3): δ 170.0, 169.8, 169.4, 169.2, 168.3, 166.2, 152.1, 145.6, 134.1, 134.0, 130.3, 128.7, 128.1, 117.0, 103.9, 101.0, 74.0, 73.6, 72.6, 71.9, 71.2, 68.6, 67.2, 62.0, 56.2, 21.0, 20.9, 20.7, 20.6, 20.5.

3.8. Preparation of (7*S*, 8*S*)-syringoylglycerol (**4**)

To a stirred mixture of **2** (146 mg, 0.27 mmol) in 3 ml of 0.1 N AcONH_4 –HOAc buffer (pH 5.6) was added β -glucosidase (5 mg), and the mixture was shaken (100 rpm) at 37 °C for 24 h. The mixture was put directly onto the cartridge column of Bond Elut C_{18} . The column was washed with H_2O (3 ml \times 3) and then with MeOH – H_2O (7:3) (3 ml \times 3). The volatile components of the MeOH – H_2O (7:3) eluents were removed to give **4** (45 mg, 0.18 mmol, 67%).

3.8.1. (7*S*, 8*S*)-Syringoylglycerol (**4**)

FD–MS m/z (rel. int.) 244 [$\text{M}]^+$ (100); IR ν_{max} (NaCl) cm^{-1} : 3360, 2940, 1614, 1519, 1463, 1428, 1216, 1113, 750; ^1H NMR (270 MHz, CD_3OD): δ 6.70 (2H, *s*), 4.55 (1H, *d*, $J = 5.9$ Hz), 3.86 (3H, *s*), 3.69 (1H, *m*), 3.50 (1H, *dd*, $J = 11.2, 3.7$ Hz), 3.30 (1H, *dd*, $J = 11.2, 6.2$ Hz); ^{13}C NMR (67.5 MHz, CD_3OD): δ 148.9, 135.8, 133.9, 105.0, 77.5, 75.5, 64.2, 56.7.

3.9. Preparation of (7*S*, 8*S*)-4-*O*-methylsyringoylglycerol (**5**)

To a stirred mixture of **4** (16 mg, 0.065 mmol) in MeOH (10 ml) cooled with an ice bath was added excess CH_2N_2 . The reaction mixture was further stirred for 1 h at 0 °C. The volatile components were removed under reduced pressure to give a colorless residue, which was purified using preparative TLC (MeOH – CHCl_3 1:9) to afford **5** (5.9 mg, 0.022 mmol, 35%).

3.9.1. (7*S*, 8*S*)-4-*O*-Methylsyringoylglycerol (**5**)

$[\alpha]_{\text{D}}^{23}$ 21.1° ($c = 0.59$, MeOH); EI–MS m/z (rel. int.): 258 (34), 198 (12), 197 (100), 196 (34), 169 (41), 154 (17), 138 (20); HR–EI–MS m/z : 258.1096 [$\text{M}]^+$ (calc. for $\text{C}_{12}\text{H}_{18}\text{O}_6$: 258.1103); IR ν_{max} (NaCl) cm^{-1} : 3383, 2940, 1593, 1506, 1463, 1422, 1328, 1235, 1125, 1005, 754; ^1H NMR (CD_3OD , 500 MHz): δ 6.71 (2H, *s*, H-2' and -6'), 4.59 (1H, *d*, $J = 2.9$ Hz, H-3), 3.84 (6H, *s*, C-3'- OMe and C-5'- OMe), 3.74 (3H, *s*, C-4'- OMe), 3.67 (1H, *m*, H-2), 3.54 (1H, *dd*, $J = 6.1, 2.4$ Hz, H-1a), 3.40 (1H, *dd*, $J = 6.1, 3.3$ Hz, H-1b).

3.10. Preparation of (2*E*) 3-(3', 4', 5'-trimethoxyphenyl) prop-2-en-1-ol (**7**)

To a stirred mixture of 3, 4, 5-trimethoxycinnamic acid (**6**, 952 mg, 4 mmol) in MeOH (20 ml) cooled with

ice bath was added excess CH_2N_2 , and the reaction mixture was further stirred at 0 °C for 1 h. The volatile components were removed under reduced pressure to give a residue. The residue was reduced using LAH (182 mg) in THF (50 ml) to give **7** (250 mg, 28%).

3.10.1. 3-(3', 4', 5'-Trimethoxyphenyl) prop-2-en-1-ol (**7**)

IR ν_{max} (NaCl) cm^{-1} : 3405, 2940, 1584, 1507, 1240, 1127, 1008; EI–MS m/z (rel. int.): 224 (100), 195 (29), 182 (57), 181 (59), 83 (28); ^1H NMR (270 MHz, CD_3OD): δ 6.61 (2H, *s*), 6.53 (1H, *d*, $J = 15.9$ Hz), 6.28 (1H, *dt*, $J = 15.9, 5.4$ Hz), 4.32 (1H, *d*, $J = 5.4$ Hz), 3.87 (6H, *s*), 3.84 (3H, *s*).

3.11. Preparation of (7*R*, 8*R*)-4-*O*-methylsyringoylglycerol (**8**)

To a stirred mixture of $\text{CH}_3\text{SO}_2\text{NH}_2$ (64 mg, 0.67 mmol) and AD-mix- β (929 mg) in a solution of *t*-BuOH– H_2O (1:1) (3 ml) was added a solution of **7** (150 mg, 0.67 mmol) in a solution of *t*-BuOH– H_2O (1:1) (7 ml). The reaction mixture was stirred at 4 °C for 24 h. To the reaction mixture was added sodium sulfite (640 mg, 5.1 mmol), and the mixture further stirred for 1 h at room temp. The reaction mixture was poured into a mixture of EtOAc (300 ml) and H_2O (150 ml). The EtOAc layer was washed with satd. aq. NaCl (50 ml \times 2) and dried over Na_2SO_4 . The volatile components of the EtOAc layer was removed under reduced pressure to give a residue, which was purified by preparative TLC (MeOH – CHCl_3 9:41) to afford **8** (15 mg, 0.058 mmol, 9%).

3.11.1. (7*R*, 8*R*)-4-*O*-Methylsyringoylglycerol (**8**)

$[\alpha]_{\text{D}}^{23}$ –17.0° ($c = 0.50$, MeOH); HR–EI–MS m/z : 258.1115 [$\text{M}]^+$ (calc. for $\text{C}_{12}\text{H}_{18}\text{O}_6$: 258.1103).

3.12. Alkaline hydrolysis of **2**

To a stirred solution of 1% NaOH/EtOH (25 ml) was added a solution of **2** (25 mg, 0.046 mmol) in MeOH (10 ml), and the reaction mixture was stirred for 5 h. The reaction mixture was treated with the resins of amberlite 120 B (Organo, 150 g). The resins was washed with MeOH (50 ml). The combined eluents were concentrated under reduced pressure, and the resultant residue was dissolved in 1 ml of MeOH – H_2O (1:9) and put onto the cartridge column of Bond Elut C_{18} . The column was washed with MeOH – H_2O (1:9) (3 ml \times 2) and then with MeOH – H_2O (4:1) (3 ml \times 2). The eluate of MeOH – H_2O (1:9) was concentrated under reduced pressure to give **1** (14 mg, 0.035 mmol, 76%), and the eluate of MeOH – H_2O (4:1) to afford **10** (50 mg, 0.034 mmol, 74%).

Acknowledgements

The authors thank Mr. Kenji Watanabe and Dr. Eri Fukusi for FAB-mass, FD-mass, EI-mass, and 2D NMR measurements.

References

- Inouye, S., Tsuruoka, T., Ito, T., Niida, T., 1968. Structure and synthesis of nojirimycin. *Tetrahedron* 23, 2125–2144.
- Kijima, H., Ide, T., Otsuka, H., Ogimi, C., Hirata, E., Takushi, A., Takeda, Y., 1997. Water-soluble phenolic glycosides from leaves of *Alangium premnifolium*. *Phytochemistry* 44, 1551–1557.
- Kolb, H.C., VanNieuwenhze, M.S., Sharpless, K.B., 1994. Catalytic asymmetric dihydroxylation. *Chem. Rev.* 94, 2483–2547.
- Matsuura, H., Asakawa, C., Kurimoto, M., Mizutani, J., 2002. α -Glucosidase inhibitor from the seeds of balsam pear (*Momordica charantia*) and the fruit of *Grifola frondosa*. *Biosci. Biotechnol. Biochem.* 66, 1576–1578.
- Reese, E.T., Parrish, F.W., 1968. Nojirimycin and D-glucono-1, 5-lactone as inhibitors of carbohydrases. *Carbohydr. Res.* 18, 381–388.
- Toda, M., Kawabata, J., Kasai, T., 2001. Inhibitory effects of ellagi- and gallotannins on rat intestinal α -glucosidase complexes. *Biosci. Biotechnol. Biochem.* 65, 542–547.
- Truscheit, E., Frommer, W., Junge, B., Muller, L., Schmidt, D.D., Wingender, W., 1981. Chemistry and biochemistry of microbial α -glucosidase inhibitors. *Angew. Chem., Int. Ed. Engl.* 20, 744–761.
- Yoshikuni, Y., 1988. Inhibition of intestinal α -glucosidase activity and postprandial hyperglycemia by moranoline and its N-acetyl derivatives. *Agric. Biol. Chem.* 52, 121–128.